NURSING EXAM TEST
[Document subtitle]
[DATE]
[COMPANY NAME]
[Company address]
, 1
1 REVIEW TEST SUBMISSION: WEEK 9 - QUIZ
Course NURS-6521N-32,Advanced Pharmacology.2016 Winter Qtr 11/28-02/19-PT27 Test
Week 9 - Quiz
Started 1/28/17 8:19 PM
Submitted 1/28/17 9:15 PM
Status Completed
Attempt 35 out of 35 points
Score
Time Elapsed 55 minutes out of 1 hour and 30 minutes
Instructions Please answer each question below and click Submit when you have
completed the Quiz.
Results Feedback
Displayed
• Question 1
1 out of 1 points
A patient will soon begin targeted therapy as a component of her
treatment plan for chronic leukemia. The nurse is conducting health
education about this new aspect of the patient's drug regimen and the
patient has asked about the potential side effects of treatment. How
should the nurse best respond?
Response Targeted therapies are generally considered to be less toxic than
Feedback: traditional chemotherapy drugs. However, adverse reactions to
targeted therapies can occur such as severe skin reactions, GI
toxicities, skin reactions, and thrombosis.
• Question 2
1 out of 1 points
Mr. Singh is a 66-year-old man who is receiving chemotherapy for the
treatment of lung cancer that has metastasized to his liver. In an effort to
prevent infection, Mr. Singh has been prescribed filgrastim (Neupogen).
Which of the nurse's following assessment questions most directly
addresses a common adverse effect of filgrastim?
Response :
Feedback
,M
e
d 2
u
l pain is a consistently observed adverse effect that can be
l attributed to drug therapy with filgrastim; it is mild to moderate
a in severity and is reported in 56% of patients taking the drug.
r Shortness of breath, mucosal bleeding, and cool, clammy skin are
y not adverse effects typical of filgrastim.
b
o
n
e
• Question 3
1 out of 1 points
An older adult woman has been diagnosed with acute lymphoblastic
leukemia (ALL) and her care team has identified potential benefits of
imatinib. Which of the following characteristics of this patient's current
health status may preclude the use of imatinib?
, Response
3
Feedback
:
Imatinib may be associated with edema. Patients should be
weighed regularly and assessed for signs of fluid retention that
could be severe. The risk of edema increases with higher doses of
imatinib and age greater than 65 years. Previous strokes,
orthopedic surgery, or well-controlled diabetes may not
contraindicate the use of imatinib.
• Question 4
1 out of 1 points
An oncology nurse is reviewing the pathophysiology of cancer and is
discussing with a colleague the factors that contribute to the success or
failure of a patient's chemotherapy. Which of the following cancerous cells
is most susceptible to the effects of chemotherapeutic drugs?
Response Cells that have a short generation time or rapid mitotic rate are
Feedback most sensitive to antineoplastic agents. All cells (both cancerous
: and noncancerous) have a blood supply. A lack of contact
inhibition is characteristic of cancer, but this is not associated
with susceptibility to chemotherapeutic drugs.
• Question 5
1 out of 1 points
A nurse is caring for a patient with cancer who has been prescribed
dronabinol (Marinol) to help reduce nausea and vomiting from
chemotherapy. The nurse will inform the patient that he or she is taking an
oral form of
Response The major ingredient of Marinol is 9-tetrahydrocannabinol
Feedback: (THC), the active ingredient in marijuana.
• Question 6
1 out of 1 points
When planning care for a patient who is receiving filgrastim (Neupogen) for
a nonmyeloid malignancy, the nurse should formulate which of the
following patient outcomes? (Select all that apply.)
Response Desired outcomes for a patient receiving filgrastim include that
Feedback febrile neutropenia will be avoided and infection and bone pain
: will not develop, or at least bone pain will not be unmanageable
if it develops. Also, because this drug is administered
subcutaneously every day during therapy, management of their
own administration would be a positive outcome for patients. A
[Document subtitle]
[DATE]
[COMPANY NAME]
[Company address]
, 1
1 REVIEW TEST SUBMISSION: WEEK 9 - QUIZ
Course NURS-6521N-32,Advanced Pharmacology.2016 Winter Qtr 11/28-02/19-PT27 Test
Week 9 - Quiz
Started 1/28/17 8:19 PM
Submitted 1/28/17 9:15 PM
Status Completed
Attempt 35 out of 35 points
Score
Time Elapsed 55 minutes out of 1 hour and 30 minutes
Instructions Please answer each question below and click Submit when you have
completed the Quiz.
Results Feedback
Displayed
• Question 1
1 out of 1 points
A patient will soon begin targeted therapy as a component of her
treatment plan for chronic leukemia. The nurse is conducting health
education about this new aspect of the patient's drug regimen and the
patient has asked about the potential side effects of treatment. How
should the nurse best respond?
Response Targeted therapies are generally considered to be less toxic than
Feedback: traditional chemotherapy drugs. However, adverse reactions to
targeted therapies can occur such as severe skin reactions, GI
toxicities, skin reactions, and thrombosis.
• Question 2
1 out of 1 points
Mr. Singh is a 66-year-old man who is receiving chemotherapy for the
treatment of lung cancer that has metastasized to his liver. In an effort to
prevent infection, Mr. Singh has been prescribed filgrastim (Neupogen).
Which of the nurse's following assessment questions most directly
addresses a common adverse effect of filgrastim?
Response :
Feedback
,M
e
d 2
u
l pain is a consistently observed adverse effect that can be
l attributed to drug therapy with filgrastim; it is mild to moderate
a in severity and is reported in 56% of patients taking the drug.
r Shortness of breath, mucosal bleeding, and cool, clammy skin are
y not adverse effects typical of filgrastim.
b
o
n
e
• Question 3
1 out of 1 points
An older adult woman has been diagnosed with acute lymphoblastic
leukemia (ALL) and her care team has identified potential benefits of
imatinib. Which of the following characteristics of this patient's current
health status may preclude the use of imatinib?
, Response
3
Feedback
:
Imatinib may be associated with edema. Patients should be
weighed regularly and assessed for signs of fluid retention that
could be severe. The risk of edema increases with higher doses of
imatinib and age greater than 65 years. Previous strokes,
orthopedic surgery, or well-controlled diabetes may not
contraindicate the use of imatinib.
• Question 4
1 out of 1 points
An oncology nurse is reviewing the pathophysiology of cancer and is
discussing with a colleague the factors that contribute to the success or
failure of a patient's chemotherapy. Which of the following cancerous cells
is most susceptible to the effects of chemotherapeutic drugs?
Response Cells that have a short generation time or rapid mitotic rate are
Feedback most sensitive to antineoplastic agents. All cells (both cancerous
: and noncancerous) have a blood supply. A lack of contact
inhibition is characteristic of cancer, but this is not associated
with susceptibility to chemotherapeutic drugs.
• Question 5
1 out of 1 points
A nurse is caring for a patient with cancer who has been prescribed
dronabinol (Marinol) to help reduce nausea and vomiting from
chemotherapy. The nurse will inform the patient that he or she is taking an
oral form of
Response The major ingredient of Marinol is 9-tetrahydrocannabinol
Feedback: (THC), the active ingredient in marijuana.
• Question 6
1 out of 1 points
When planning care for a patient who is receiving filgrastim (Neupogen) for
a nonmyeloid malignancy, the nurse should formulate which of the
following patient outcomes? (Select all that apply.)
Response Desired outcomes for a patient receiving filgrastim include that
Feedback febrile neutropenia will be avoided and infection and bone pain
: will not develop, or at least bone pain will not be unmanageable
if it develops. Also, because this drug is administered
subcutaneously every day during therapy, management of their
own administration would be a positive outcome for patients. A
